NEW YORK, NY / ACCESSWIRE / July 27, 2017 / Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ('United Therapeutics' or the 'Company') (NASDAQ: UTHR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether United Therapeutics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On July 27, 2017, United Therapeutics disclosed that it recorded a $210 million accrual relating to a potential settlement in connection with a U.S. Department of Justice investigation into the Company's possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act.
On this news, United Therapeutics' share price has fallen as much as $8.35, or 6.35%, during intraday trading on July 27, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP
